Campbell & CO Investment Adviser LLC Trims Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Campbell & CO Investment Adviser LLC lessened its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report) by 44.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,895 shares of the company’s stock after selling 25,379 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Kiniksa Pharmaceuticals were worth $554,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of Kiniksa Pharmaceuticals by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 128,778 shares of the company’s stock worth $1,813,000 after acquiring an additional 828 shares during the last quarter. Legal & General Group Plc lifted its holdings in Kiniksa Pharmaceuticals by 7.8% during the 4th quarter. Legal & General Group Plc now owns 11,712 shares of the company’s stock valued at $175,000 after buying an additional 850 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Kiniksa Pharmaceuticals by 0.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 205,557 shares of the company’s stock valued at $3,079,000 after buying an additional 1,057 shares in the last quarter. Royal Bank of Canada lifted its holdings in Kiniksa Pharmaceuticals by 44.2% during the 2nd quarter. Royal Bank of Canada now owns 3,523 shares of the company’s stock valued at $50,000 after buying an additional 1,080 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Kiniksa Pharmaceuticals by 19.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,549 shares of the company’s stock valued at $83,000 after buying an additional 1,385 shares in the last quarter. Institutional investors own 47.31% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

NASDAQ KNSA opened at $20.55 on Tuesday. The company’s 50-day simple moving average is $18.39 and its two-hundred day simple moving average is $17.27. Kiniksa Pharmaceuticals, Ltd. has a one year low of $10.29 and a one year high of $20.94.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $20.00, for a total transaction of $240,000.00. Following the transaction, the chief financial officer now owns 15,632 shares of the company’s stock, valued at approximately $312,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 16,670 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $19.17, for a total transaction of $319,563.90. Following the transaction, the chief accounting officer now owns 17,005 shares of the company’s stock, valued at approximately $325,985.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Ragosa sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $20.00, for a total transaction of $240,000.00. Following the transaction, the chief financial officer now directly owns 15,632 shares in the company, valued at approximately $312,640. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,586 shares of company stock valued at $1,242,569. Company insiders own 54.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals from $23.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, January 2nd. TheStreet lowered shares of Kiniksa Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, November 3rd.

Get Our Latest Stock Report on Kiniksa Pharmaceuticals

About Kiniksa Pharmaceuticals

(Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Articles

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report).

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.